Drug Manufacturing

Bavarian Nordic and SII sign agreement for chikungunya vaccine production

Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract for its chikungunya vaccine (CHIKV VLP).

CordenPharma leases space at Flatiron Park for peptides development

US-based CordenPharma Colorado has leased a 64,000ft² space at BioMed Realty’s Flatiron Park’s 5505 Central, which marks Boulder’s first purpose-built speculative lab building, for peptides development.

NorthX Biologics and Demeetra collaborate on GMP manufacturing and CLD

NorthX Biologics and Demeetra have entered a strategic partnership focused on integrated cell line development (CLD) and good manufacturing practice (GMP) manufacturing.

AbbVie announces $380m investment in North Chicago API facilities

AbbVie has announced plans to invest $380m to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago site in Illinois, US.

Ampersand Capital acquires Purna Pharmaceuticals

Ampersand Capital Partners has acquired Purna Pharmaceuticals, a Belgium-based provider of development and manufacturing services for liquid and semi-solid dosage forms in the pharmaceutical sector.

DeepHow introduces PharmaCloud for pharmaceutical manufacturers

DeepHow has launched PharmaCloud, a good manufacturing practice (GMP)-compliant cloud environment developed specifically to standardise AI-driven operator training in pharma manufacturing.

iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson’s

iRegene Therapeutics has received regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its lead product, NouvNeu001, aimed at treating Parkinson’s disease.

AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy

AstraZeneca has agreed to purchase AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.

Novartis to build fourth US radioligand therapy facility in Florida

Novartis has announced plans to construct a radioligand therapy (RLT) manufacturing facility in Winter Park, Florida, as part of its ongoing radioligand therapy manufacturing expansion.